Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2959 - 2959

Published: March 25, 2025

Metabolic-dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is a highly prevalent metabolic disorder characterized by hepatic steatosis in conjunction with at least one cardiometabolic risk factor, such obesity, type 2 diabetes, hypertension, or dyslipidemia. As global rates of obesity and syndrome continue to rise, MASLD becoming major public health concern, projections indicating substantial increase prevalence over the coming decades. The spectrum ranges from simple metabolic-dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, hepatocellular carcinoma, contributing significant morbidity mortality worldwide. This review delves into molecular mechanisms driving pathogenesis, including dysregulation lipid metabolism, chronic inflammation, oxidative stress, mitochondrial dysfunction, gut microbiota alterations. Recent advances research have highlighted role genetic epigenetic factors progression, well novel therapeutic targets peroxisome proliferator-activated receptors (PPARs), fibroblast growth factors, thyroid hormone receptor beta agonists. Given multifaceted nature MASLD, multidisciplinary approach integrating early diagnosis, insights, lifestyle interventions, personalized therapies critical. underscores urgent need for continued innovative treatment strategies precision medicine approaches halt progression improve patient outcomes.

Language: Английский

Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: a nationwide study

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 3, 2025

Language: Английский